Technical Analysis for GRI - GRI Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.39 | -2.23% | -0.01 |
GRI closed down 2.23 percent on Wednesday, May 8, 2024, on 67 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -2.23% | |
| Expansion Breakdown | Bearish Swing Setup | -2.23% | |
| Stochastic Buy Signal | Bullish | -2.23% | |
| New 52 Week Low | Weakness | -2.23% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 13 hours ago |
| Gap Up Closed | about 15 hours ago |
| Reversed from Up | about 15 hours ago |
| 1.5x Volume Pace | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Autoimmunity Liver Disease Natural Killer Cell Lymphocytes T Cell Natural Killer T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Autoimmunity Liver Disease Natural Killer Cell Lymphocytes T Cell Natural Killer T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 49.28 |
| 52 Week Low | 0.375 |
| Average Volume | 155,234 |
| 200-Day Moving Average | 6.25 |
| 50-Day Moving Average | 0.63 |
| 20-Day Moving Average | 0.46 |
| 10-Day Moving Average | 0.42 |
| Average True Range | 0.05 |
| RSI (14) | 21.26 |
| ADX | 15.68 |
| +DI | 15.06 |
| -DI | 25.71 |
| Chandelier Exit (Long, 3 ATRs) | 0.44 |
| Chandelier Exit (Short, 3 ATRs) | 0.52 |
| Upper Bollinger Bands | 0.55 |
| Lower Bollinger Band | 0.36 |
| Percent B (%b) | 0.14 |
| BandWidth | 40.86 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0102 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.43 | ||||
| Resistance 3 (R3) | 0.44 | 0.43 | 0.43 | ||
| Resistance 2 (R2) | 0.43 | 0.42 | 0.43 | 0.42 | |
| Resistance 1 (R1) | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 |
| Pivot Point | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
| Support 1 (S1) | 0.38 | 0.39 | 0.38 | 0.38 | 0.36 |
| Support 2 (S2) | 0.37 | 0.38 | 0.37 | 0.36 | |
| Support 3 (S3) | 0.35 | 0.37 | 0.35 | ||
| Support 4 (S4) | 0.35 |
